R&D
Home > R&D
Innovation System

Through years of continuous effort, the company has built an increasingly comprehensive innovation system.

Global Innovation Layout

XX Pharmaceuticals has established 14 R&D centers in the United States, Europe, Australia, Japan, and China, creating a global R&D system with distinct strengths and complementary functions.

Innovative Talent

After years of development, the company has formed a large-scale, professional, and comprehensive R&D team of over 5,600 people. This team has developed a competitive advantage in innovation and execution capabilities across multiple disease research areas, providing strong talent support for the company's high-quality development.

Innovative Technology Platforms

The company has established a number of internationally leading new technology platforms, such as PROTACs, peptides, monoclonal antibodies, bispecific antibodies, multispecific antibodies, ADCs, and radioligand therapy, providing a strong foundation for innovative R&D.

XX Pharmaceuticals

Adhering to a development strategy prioritizing technological innovation, XX Pharmaceuticals continuously strengthens its R&D system and capabilities.

Production System

XX Pharmaceutical has established a production and quality control system that meets US, EU, and Japanese standards.

 

Production Bases Are Located Throughout China, Creating World-Class Production Lines.

 

Internal control standards exceeding legal standards have been established, and the control of exported products meets or exceeds global quality standards such as EU GMP, US cGMP, and ICH quality guidelines.

 

The company continuously improves its full-process management from R&D and production to product launch, implementing comprehensive product quality control and service quality management with high standards and strict requirements. All production lines for the company's marketed products have passed GMP inspections, and the company has established internationally standardized production workshops with advanced production equipment.

The company has established a comprehensive safety production management system and rigorously implements all safety production measures. The company has passed the ISO 45001 Occupational Health and Safety Management System recertification.

International high-standard production base

A well-defined and collaborative production system has been established.

"National Innovative Enterprise" recognized by the Ministry of Science and Technology and other three ministries

The group boasts a top-tier high-tech drug incubation base in China—the Central Pharmaceutical Research Institute—and R&D and clinical centers in California, Princeton, Texas, and New Jersey, USA.

 

It invests 5.7 billion yuan annually in R&D. Currently, it has established a 2,000-person R&D team, including thousands of highly educated professionals with master's and doctoral degrees. It has built a comprehensive R&D system in innovative drugs, generic drugs, biologics, and antibody drugs, ranking among the top R&D-oriented pharmaceutical companies in China.

21.9%
Research and development expenses as a percentage of drug revenue
5.7billion
Annual R&D Revenue
2000
R&D Team
300+
Ongoing Projects
300+
PhDs and Overseas High-Level R&D Talent
Get Everything You Need In One Place

Welcome to submit any questions and suggestions. We will reply to you as soon as possible. Thank you for your support and help.

Contact us
Eight Major Innovative Technology Platforms
Antibody/Fusion Protein Technology Platform

JMT203(GFRAL)

JMT106 ( GPC3 / IFNa ) JMT206 ( ACtRIA / B )

JMT108(PD-1/1L-15)

Nanomedicine Technology Platform

Mitoxantrone liposomes

Docetaxel albumin

Paclitaxel cationic liposomes

Irinotecan liposomes

Small Molecule Drug Screening And Development Platform

SYH2071(LP(a))

SYHX1901 (AK/TYK)

Plugletine (DPP4)

SYH2039(MAT2A)

Cell Therapy Technology Platform

SYS6020(BCMA CAR-T)

SYS6063(CD19/BCMA CAR-T)

Research And Development Pipeline
Anti-tumor
Anti-tumor
Neuropsychiatry
Neuropsychiatry
Cardiovascular system
Cardiovascular system
Digestion and metabolism
Digestion and metabolism
Anti-infection
Anti-infection
Autoimmunity
Autoimmunity
Hematologic Tumors
Leukemia
Lymphoma
Myeloma
Solid tumors
Lung cancer
Breast cancer
Ovarian cancer
Colorectal cancer
Pancreatic cancer
Stomach cancer
Liver cancer
Kidney cancer
Others
Key New Drug Projects Under Development
Innovative Chemical Drugs
Innovative Biologics
Novel Formulations

1 product commercialized, 2 NDAs submitted, 7 in pivotal clinical stages, and over 10 in clinical development stages

 

Therapeutic areas Lead candidate drugs Indications
Digestion and Metabolism Hydroxycobalamin Hydrochloride Injection Methylmalonic acidemia
Psychiatry and Neurology Dextromethorphan/Bupropion Extended-Release Tablets Depression
Cardiovascular Valsartan/Levoamdipine Maleate Hypertension
Digestion and Metabolism SYH2068 Hyperalbumin(a)emia
Cardiovascular SYH2046 Heart failure after acute myocardial infarction
Digestion and Metabolism SYS2062 Hypertension
Respiration SYH2059 Interstitial lung disease
Digestion and Metabolism SYH2053 Primary hypercholesterolemia and mixed hyperlipidemia in adults
Digestion and Metabolism Smegglutide Injection Substages of type 2 diabetes, substages of weight loss/obesity
Anti-tumor SYH2051 Advanced cancer
Anti-tumor SYH2045 Advanced cancer
Anti-tumor SYH2043 Breast cancer
Patent Protection National Project
2,282.00
Patent application
1,024.00
Patent grant
338.00
Patent applied for in 2024
93.00
Patent granted in 2024
In 2,011.00
Enbipu wins China Patent Gold Award
In 2,013.00
National Intellectual Property Demonstration Enterprise
In 2,017.00
Jinyouli wins China Patent Gold Award
In 2,018.00
Intellectual Property Management System Certification
National-Level Awards, National-Level Honors
Certificate name
Certificate name
Licensing, Importation, Acquisition (E.G.)
CSPC&MADRIGAL

Shijiazhuang Pharmaceutical Group and Madrigal Pharmaceuticals, Inc. (Madrigal) have entered into an exclusive licensing agreement for the global development, production and commercialization of SYH2086, an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.

CSPC&ASTRAZENEC

CSPC Pharmaceutical Group has entered into a strategic R&D collaboration agreement with AstraZeneca, a global leader in biopharmaceuticals, to leverage the Group’s AI-driven, high-efficiency drug discovery platform to discover and develop novel oral small molecule drug candidates.

CSPC&CIPLA USA

Shijiazhuang Pharmaceutical Group and CIPLA USA, INC. entered into an exclusive licensing agreement for the commercialization of irinotecan liposome injection in the United States.

CSPC&RADIANCE BIOPHARMA

Shijiazhuang Pharmaceutical Group has entered into an exclusive licensing agreement with Radiance Biopharma for the development and commercialization of the antibody-drug conjugate SYS6005 in the United States, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia, and Canada.